{"id":2356,"date":"2025-10-06T10:43:52","date_gmt":"2025-10-06T10:43:52","guid":{"rendered":"https:\/\/www.merckconnect.com\/zerbaxa\/?page_id=2356"},"modified":"2026-03-24T09:48:02","modified_gmt":"2026-03-24T09:48:02","slug":"idsa-guidance","status":"publish","type":"page","link":"https:\/\/www.merckconnect.com\/zerbaxa\/idsa-guidance\/","title":{"rendered":"select IDSA guidance"},"content":{"rendered":"<link rel='stylesheet' id='vivid360-paragraph-css-css' href='https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/themes\/cex-wpvip-mhh-merck-vivid360-theme-1-12\/blocks\/custom-paragraph\/css\/style.min.css?ver=1766071753' media='all' \/>\n<p  class=\"vivid360-paragraph\" style=\"--desktopfontsize:16px;--desktoplineheight:24px;--tabletfontsize:16px;--tabletlineheight:24px;--mobilefontsize:16px;--mobilelineheight:24px;\" dir=\"ltr\">\n\n<\/p>\n\n<link rel='stylesheet' id='vivid360-spacer-css-css' href='https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/themes\/cex-wpvip-mhh-merck-vivid360-theme-1-12\/blocks\/spacer\/css\/style.min.css?ver=1766071753' media='all' \/>\n\n<div style=\"background-color:transparent;--desktop-spacer:24px;--mobile-spacer:24px;--tablet-spacer:24px\" class=\"wp-block-vivid360-spacer vivid360-spacer-desktop vivid360-spacer-mobile vivid360-spacer-tablet\"><\/div>\n\n\n<link rel='stylesheet' id='vivid360-heading-css-css' href='https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/themes\/cex-wpvip-mhh-merck-vivid360-theme-1-12\/blocks\/heading\/css\/style.min.css?ver=1766071753' media='all' \/>\n\n<div class=\"vivid360-heading default-hcp-tablet-fontsize\" id=\"a59f56cde-893d-48d1-8ab2-5a289895a918\"><h1 class=\"content-width fontWeightRegular\" style=\"color:#333333;--desktopFontSize:30px;--tabletFontSize:var(--h1FontSizeDesktop);--mobileFontSize:24px;--desktopLineHeightSize:45px;--tabletLineHeightSize:var(--h1LineHeightDesktop);--mobileLineHeightSize:\" id=\"\"><strong>2024 IDSA Guidance* includes:<\/strong><\/h1><\/div>\n\n\n\n<div style=\"background-color:transparent;--desktop-spacer:2px;--mobile-spacer:8px;--tablet-spacer:2px\" class=\"wp-block-vivid360-spacer vivid360-spacer-desktop vivid360-spacer-mobile vivid360-spacer-tablet\"><\/div>\n\n\n<link rel='stylesheet' id='vivid360-list-parent-css-css' href='https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/themes\/cex-wpvip-mhh-merck-vivid360-theme-1-12\/blocks\/list-parent\/css\/style.css?ver=1766071753' media='all' \/>\n\n<div class=\"vivid-block-list2 content-width  \">\n<ul style=\"--listBulletColor:#333\" class=\"list-bullet-color has-medium-font-size\">\n<li class=\"has-medium-font-size\"><strong><span class=\"word-break\"><mark style=\"background-color:rgba(0, 0, 0, 0);color:#333333\" class=\"has-inline-color\">Ceftolozane-tazobactam for the treatment of certain infections caused by MDR <em>P. aeruginosa<\/em> in critically ill patients or patients with poor source control<sup>1,a<\/sup><\/mark><\/span><\/strong><\/li>\n\n\n\n<li class=\"has-medium-font-size\"><strong><span class=\"word-break\"><mark style=\"background-color:rgba(0, 0, 0, 0);color:#333333\" class=\"has-inline-color\">Ceftolozane-tazobactam for treatment of select polymicrobial infections such as those caused by both ESBL-E and <em><span class=\"no-wrap-text\">P. aeruginosa<\/span><\/em> with certain mechanisms of resistance.<sup>1,a<\/sup><\/mark><\/span><\/strong><\/li>\n<\/ul>\n<\/div>\n\n\n\n<div style=\"background-color:transparent;height:8px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-8\"><\/div>\n\n\n\n<div class=\"paragraph-wrapper wp-elements-fad3520d8b56133a295fd24837dd51f3\"><div class=\"_b03535ed-fe9d-4b42-8c6c-8bc595f213cf \" id=\"\"><p class=\"has-text-color has-link-color\" style=\"color:#333333;font-size:14px\">*2024 Infectious Diseases Society of America (IDSA) Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.<sup>1<\/sup><\/p><\/div><\/div>\n\n\n\n<div class=\"paragraph-wrapper wp-elements-e3942ad93a737012c222408d7ba3e0c2\"><div class=\"_7037ad76-65db-411a-92f9-d32cbbdef946 \" id=\"\"><p class=\"has-text-color has-link-color\" style=\"color:#333333;font-size:14px\"><sup>a<\/sup>Dosing suggestions in IDSA guidance for several agents may differ from dosing in approved labels.<\/p><\/div><\/div>\n\n\n\n<div style=\"background-color:transparent;--desktop-spacer:24px;--mobile-spacer:32px;--tablet-spacer:24px\" class=\"wp-block-vivid360-spacer vivid360-spacer-desktop vivid360-spacer-mobile vivid360-spacer-tablet\"><\/div>\n\n\n\n<div class=\"vivid360-heading default-hcp-tablet-fontsize\" id=\"a4d55578f-7190-4658-9dd3-1fbf0b169d64\"><h2 class=\"has-primary-color content-width fontWeightRegular\" style=\"--desktopFontSize:24px;--tabletFontSize:var(--h2FontSizeDesktop);--mobileFontSize:20px;--desktopLineHeightSize:36px;--tabletLineHeightSize:var(--h2LineHeightDesktop);--mobileLineHeightSize:\" id=\"\"><strong>Dosing and administration<\/strong><\/h2><\/div>\n\n\n\n<div style=\"background-color:transparent;--desktop-spacer:0px;--mobile-spacer:8px;--tablet-spacer:0px\" class=\"wp-block-vivid360-spacer vivid360-spacer-desktop vivid360-spacer-mobile vivid360-spacer-tablet\"><\/div>\n\n\n\n<div class=\"vivid360-heading\" id=\"a95bc45ce-3b29-42c6-b693-f26c77a26be3\"><h3 class=\"content-width fontWeightBold\" style=\"color:#333333;--desktopFontSize:20px;--tabletFontSize:var(--h3FontSizeDesktop);--mobileFontSize:18px;--desktopLineHeightSize:30px;--tabletLineHeightSize:var(--h3LineHeightDesktop);--mobileLineHeightSize:\" id=\"\"><strong>Approved dosage for adults patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia <strong>(HABP\/VABP)<sup>b,c<\/sup><\/strong><\/strong><\/h3><\/div>\n\n\n\n<div style=\"background-color:transparent;--desktop-spacer:0px;--mobile-spacer:8px;--tablet-spacer:0px\" class=\"wp-block-vivid360-spacer vivid360-spacer-desktop vivid360-spacer-mobile vivid360-spacer-tablet\"><\/div>\n\n\n\n<p class=\"has-text-color has-link-color wp-elements-194655c77ac7ddc42cbb437016b8fbf2\" style=\"color:#000000\">The recommended dose of ZERBAXA in adult patients 18 years and older with HABP\/VABP and creatinine clearance (CrCI) greater than <span class=\"no-wrap-text\">50 mL\/min<\/span> is <span class=\"no-wrap-text\">3 grams (two 1.5 g vials)<\/span> over <span class=\"no-wrap-text\">1-hour<\/span> period every <span class=\"no-wrap-text\">8 hours<\/span> for 8 to 14 days. The duration of therapy should be guided by the severity and site of infection and the patient&#8217;s clinical and bacteriological progress.<\/p>\n\n\n\n<div style=\"background-color:transparent;--desktop-spacer:16px;--mobile-spacer:24px;--tablet-spacer:16px\" class=\"wp-block-vivid360-spacer vivid360-spacer-desktop vivid360-spacer-mobile vivid360-spacer-tablet\"><\/div>\n\n\n\n<div class=\"vivid360-heading\" id=\"a062fef03-7bbb-4031-8cb7-d8bf6180fca1\"><h3 class=\"content-width fontWeightRegular\" style=\"--desktopFontSize:var(--h3FontSizeDesktop);--tabletFontSize:var(--h3FontSizeDesktop);--mobileFontSize:var(--h3FontSizeMobile);--desktopLineHeightSize:var(--h3LineHeightDesktop);--tabletLineHeightSize:var(--h3LineHeightDesktop);--mobileLineHeightSize:\" id=\"\"><strong>Renal dosing adjustments for adult patients with HABP\/VABP per estimated CrCI (mL\/min)<sup>b,c<\/sup><\/strong><\/h3><\/div>\n\n\n\n<div class=\"vivid-block-list2 content-width  \">\n<ul style=\"color:#000000;--listBulletColor:#333\" class=\"list-bullet-color has-dark-text-color has-text-color has-link-color wp-elements-b53a0096b4ca1dcc3b13ffeb20ebac8b\">\n<li><strong>30 to 50 CrCI (mL\/min)<\/strong> <span class=\"no-wrap-text\">1.5 g (1 g and 0.5 g)<\/span> intravenously every 8 hours<\/li>\n\n\n\n<li><strong>15 to 29 CrCI (mL\/min)<\/strong> <span class=\"no-wrap-text\">750 mg<\/span> <span class=\"no-wrap-text\">(500 mg and 250 mg)<\/span> intravenously every <span class=\"no-wrap-text\">8 hours<\/span><\/li>\n\n\n\n<li>For patients with end-stage renal disease on hemodialysis: a single loading dose of 2.25 g <span class=\"no-wrap-text\">(1.5 g and 0.75 g)<\/span> followed by a 450-mg <span class=\"no-wrap-text\">(300 mg and 150 mg)<\/span> maintenance dose administered intravenously every 8 hours for the remainder of the treatment period (on hemodialysis days, administer the dose at the earliest possible time following completion of dialysis).<\/li>\n\n\n\n<li>The duration of therapy should be guided by the severity and site of infection and the patient&#8217;s clinical and bacteriological progress.<\/li>\n\n\n\n<li>For patients with changing renal function, monitor CrCl at least daily and adjust dosage of ZERBAXA accordingly.<\/li>\n<\/ul>\n<\/div>\n\n\n\n<div class=\"paragraph-wrapper wp-elements-1090cc7c9d9f214c49f4a03d64daf0ca\"><div class=\"_7bfe90c5-bc00-4f1b-97a4-571cdf96752d \" id=\"\"><p class=\"has-text-color has-link-color\" style=\"color:#000000;font-size:14px\"><sup>b<\/sup>Creatinine clearance (CrCI) estimated using Cockcroft-Gault formula. <\/p><\/div><\/div>\n\n\n\n<div class=\"paragraph-wrapper wp-elements-4f70c77b7a29a3ab6a2072d79bfdd97c\"><div class=\"_5474219f-a3e9-4bc1-adc1-4dbd5e99f24e \" id=\"\"><p class=\"has-text-color has-link-color\" style=\"color:#000000;font-size:14px\"><sup>c<\/sup>All doses of ZERBAXA are administered over 1 hour.<\/p><\/div><\/div>\n\n\n\n<div style=\"background-color:transparent;--desktop-spacer:24px;--mobile-spacer:24px;--tablet-spacer:24px\" class=\"wp-block-vivid360-spacer vivid360-spacer-desktop vivid360-spacer-mobile vivid360-spacer-tablet\"><\/div>\n\n\n<link rel='stylesheet' id='vivid360-card-css-css' href='https:\/\/www.merckconnect.com\/zerbaxa\/wp-content\/themes\/cex-wpvip-mhh-merck-vivid360-theme-1-12\/blocks\/card\/css\/style.min.css?ver=1773241827' media='all' \/>\n\n<div id=\"\" class=\"wp-block-vivid360-card a7fcab46c-3e79-41df-acb7-1dd11b96515c vivid360-block-card has-text-align-left hasBoxShadow card-basic full-page-width\" style=\"border-width:0px;border-style:;border-radius:0;color:#111 !important;border-color:#333333\"><div class=\"card-content\"><div class=\"card-content-wrap\"><h3 class=\"card-header fontWeightBold\"><mark style=\"background-color:rgba(0, 0, 0, 0);color:#333333\" class=\"has-inline-color\">For information on dosing and administration for cIAI and cUTI:<\/mark><\/h3><div class=\"card-desc has-regular-font-size\">\n<p class=\"has-primary-color has-text-color has-link-color wp-elements-b43cf4adb1afbf6245cdaeb40f0d597b\"><a aria-label=\"#\" href=\"https:\/\/www.merckconnect.com\/zerbaxa\/dosing-administration\/#Dosing-4\">Dosage for adult patients with cIAI and cUTI<\/a><\/p>\n<\/div><\/div><\/div><\/div>\n\n\n\n<div style=\"background-color:transparent;--desktop-spacer:24px;--mobile-spacer:24px;--tablet-spacer:24px\" class=\"wp-block-vivid360-spacer vivid360-spacer-desktop vivid360-spacer-mobile vivid360-spacer-tablet\"><\/div>\n\n\n\n<div class=\"vivid360-heading default-hcp-fontsize default-hcp-tablet-fontsize default-hcp-mobile-fontsize\" id=\"a91dfb7b7-5eef-4102-ba3a-fb35b2550470\"><h2 class=\"content-width fontWeightRegular\" style=\"--desktopFontSize:var(--h2FontSizeDesktop);--tabletFontSize:var(--h2FontSizeDesktop);--mobileFontSize:var(--h2FontSizeMobile);--desktopLineHeightSize:var(--h2LineHeightDesktop);--tabletLineHeightSize:var(--h2LineHeightDesktop);--mobileLineHeightSize:\" id=\"\"><strong>Reference<\/strong><\/h2><\/div>\n\n\n\n<div class=\"vivid-block-list2 content-width  \">\n<ol style=\"--listBulletColor:#333\" class=\"list-bullet-color has-small-font-size\">\n<li>Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. <em>Clin Infect Dis<\/em>. Published online August 7, 2024. doi:10.1093\/cid\/ciae403<\/li>\n<\/ol>\n<\/div>\n\n\n\n<div style=\"background-color:transparent;height:32px\" class=\"wp-block-vivid360-spacer vivid360-spacer spacer-32\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>*2024 Infectious Diseases Society of America (IDSA) Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.1 aDosing suggestions in IDSA guidance for several&#8230;<\/p>\n","protected":false},"author":5494,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[],"ga4_page_businessunit":[],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[],"ga4_page_product":[],"ga4_page_region":[],"ga4_page_therapeuticarea":[],"user_role":[],"mhh-area-of-interest":[],"access":[],"user_status":[],"class_list":["post-2356","page","type-page","status-publish"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IDSA Guidance for ZERBAXA\u00ae (ceftolozane and tazobactam)<\/title>\n<meta name=\"description\" content=\"Read about the IDSA guidance for ZERBAXA\u00ae (ceftolozane and tazobactam), including dosing information for certain adult patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.com\/zerbaxa\/idsa-guidance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IDSA Guidance for ZERBAXA\u00ae (ceftolozane and tazobactam)\" \/>\n<meta property=\"og:description\" content=\"Read about the IDSA guidance for ZERBAXA\u00ae (ceftolozane and tazobactam), including dosing information for certain adult patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.com\/zerbaxa\/idsa-guidance\/\" \/>\n<meta property=\"og:site_name\" content=\"zerbaxa\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-24T09:48:02+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IDSA Guidance for ZERBAXA\u00ae (ceftolozane and tazobactam)","description":"Read about the IDSA guidance for ZERBAXA\u00ae (ceftolozane and tazobactam), including dosing information for certain adult patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.com\/zerbaxa\/idsa-guidance\/","og_locale":"en_US","og_type":"article","og_title":"IDSA Guidance for ZERBAXA\u00ae (ceftolozane and tazobactam)","og_description":"Read about the IDSA guidance for ZERBAXA\u00ae (ceftolozane and tazobactam), including dosing information for certain adult patients.","og_url":"https:\/\/www.merckconnect.com\/zerbaxa\/idsa-guidance\/","og_site_name":"zerbaxa","article_modified_time":"2026-03-24T09:48:02+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/idsa-guidance\/","url":"https:\/\/www.merckconnect.com\/zerbaxa\/idsa-guidance\/","name":"IDSA Guidance for ZERBAXA\u00ae (ceftolozane and tazobactam)","isPartOf":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/#website"},"datePublished":"2025-10-06T10:43:52+00:00","dateModified":"2026-03-24T09:48:02+00:00","description":"Read about the IDSA guidance for ZERBAXA\u00ae (ceftolozane and tazobactam), including dosing information for certain adult patients.","breadcrumb":{"@id":"https:\/\/www.merckconnect.com\/zerbaxa\/idsa-guidance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.com\/zerbaxa\/idsa-guidance\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/idsa-guidance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.com\/zerbaxa\/"},{"@type":"ListItem","position":2,"name":"select IDSA guidance"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.com\/zerbaxa\/#website","url":"https:\/\/www.merckconnect.com\/zerbaxa\/","name":"zerbaxa","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.com\/zerbaxa\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/2356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/users\/5494"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/comments?post=2356"}],"version-history":[{"count":5,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/2356\/revisions"}],"predecessor-version":[{"id":2570,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/pages\/2356\/revisions\/2570"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/media?parent=2356"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_audience?post=2356"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_birn_id?post=2356"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_branding?post=2356"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_businessunit?post=2356"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_campaign?post=2356"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=2356"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=2356"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=2356"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_experience?post=2356"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_indication?post=2356"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_material_intent?post=2356"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_product?post=2356"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_region?post=2356"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=2356"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/user_role?post=2356"},{"taxonomy":"mhh-area-of-interest","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/mhh-area-of-interest?post=2356"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/access?post=2356"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.merckconnect.com\/zerbaxa\/wp-json\/wp\/v2\/user_status?post=2356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}